vaccine booster

TWiV 853: COVID-19 clinical update #97 with Dr. Daniel Griffin

2 Comments / This Week in Virology / By

In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for …

TWiV 853: COVID-19 clinical update #97 with Dr. Daniel Griffin Read More »

TWiV 850: COVID-19 clinical update #96 with Dr. Daniel Griffin

This Week in Virology / By

In COVID-19 clinical update #96, Daniel Griffin reviews Omicron in South Africa, rapid antigen tests, viral coinfections, isolation and quarantine, saliva preferred for Omicron, risk factors for severe disease in vaccinated, Paxlovid dosing, and long COVID. Click arrow to playDownload TWiV 850 (58 MB .mp3, 48 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv

TWiV 845: COVID-19 clinical update #94 with Dr. Daniel Griffin

This Week in Virology / By

In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients. Hosts: Daniel Griffin and Vincent Racaniello Click arrow to playDownload TWiV 845 (58 MB .mp3, 48 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show …

TWiV 845: COVID-19 clinical update #94 with Dr. Daniel Griffin Read More »

TWiV 840: COVID-19 clinical update #92 with Dr. Daniel Griffin

3 Comments / This Week in Virology / By

In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly’s cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long …

TWiV 840: COVID-19 clinical update #92 with Dr. Daniel Griffin Read More »

TWiV 834: COVID-19 clinical update #90 with Dr. Daniel Griffin

This Week in Virology / By

In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 after vaccination and infection. Click …

TWiV 834: COVID-19 clinical update #90 with Dr. Daniel Griffin Read More »

TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin

This Week in Virology / By

In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals. Click arrow to playDownload TWiV 831 (20 MB .mp3, …

TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin Read More »

Scroll to Top